Sphera Funds Management LTD. Takes Position in Zura Bio Limited (NASDAQ:ZURA)

Sphera Funds Management LTD. bought a new position in shares of Zura Bio Limited (NASDAQ:ZURAFree Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 738,718 shares of the company’s stock, valued at approximately $2,999,000. Sphera Funds Management LTD. owned approximately 1.10% of Zura Bio as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ZURA. Braidwell LP acquired a new stake in Zura Bio in the 3rd quarter valued at about $10,040,000. Point72 Asset Management L.P. acquired a new stake in Zura Bio in the 2nd quarter valued at about $8,446,000. Great Point Partners LLC increased its position in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after acquiring an additional 1,884,501 shares in the last quarter. Armistice Capital LLC increased its position in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares in the last quarter. Finally, State Street Corp increased its position in Zura Bio by 47.5% in the 3rd quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after acquiring an additional 127,300 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZURA. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Monday, November 18th. Leerink Partners started coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Finally, Chardan Capital reduced their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Read Our Latest Research Report on ZURA

Insider Activity

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.10% of the stock is currently owned by company insiders.

Zura Bio Trading Up 1.5 %

NASDAQ ZURA opened at $2.74 on Thursday. Zura Bio Limited has a 12-month low of $2.00 and a 12-month high of $6.35. The firm’s 50 day moving average is $3.99 and its 200-day moving average is $3.94.

Zura Bio (NASDAQ:ZURAGet Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, research analysts predict that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Zura Bio Profile

(Free Report)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

Featured Stories

Want to see what other hedge funds are holding ZURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zura Bio Limited (NASDAQ:ZURAFree Report).

Institutional Ownership by Quarter for Zura Bio (NASDAQ:ZURA)

Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.